Maternal depression during pregnancy and offspring depression in adulthood: Role of child maltreatment

Plant, Dominic; Pariante, Carmine M.; Sharp, Deborah; Pawlby, Susan

doi:10.1192/bjp.bp.114.156620

Cited by 157 publications

(151 citation statements)

References 56 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Data collected in the same offspring at age 25 were consistent with these earlier findings (Plant et al, 2015a). Evidence from the same study also shows that antenatal depression increases the risk of the offspring being exposed to maltreatment in childhood, by approximately 4-fold (Pawlby et al, 2011), especially if the mother was herself exposed to maltreatment in childhood (Plant et al, 2013).…”

Section: Risks Of Untreated Antenatal Illness On the Infants Developmsupporting

confidence: 80%

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

et al. 2017

View full text Add to dashboard Cite

Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, due to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.

show abstract

Section: Risks Of Untreated Antenatal Illness On the Infants Developmsupporting

confidence: 80%

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It affects 10–20% of new mothers within 1 year following delivery and deeply impacts maternal life quality as well as being a risk factor for maternal suicide . Further, PDS has a negative impact on family relationships including marital and maternal‐infant interactions, with resultant poorer physiologic and psychological health of the offspring . Consequently, PDS has been extensively investigated with a view to both treatment and prevention.…”

Section: Introductionmentioning

confidence: 99%

Dexmedetomidine Alleviates Postpartum Depressive Symptoms following Cesarean Section in Chinese Women: A Randomized Placebo‐Controlled Study

Wang

Quan

et al. 2019

Pharmacotherapy

View full text Add to dashboard Cite

Objectives Few studies have investigated the prophylactic efficacy of dexmedetomidine (DEX) in postpartum depressive symptoms (PDS). A randomized double‐blind placebo‐controlled trial was conducted to investigate whether the administration of DEX, immediately after delivery and for patient‐controlled intravenous analgesia (PCIA), can attenuate PDS. Methods A total of 600 parturients scheduled for elective cesarean delivery under spinal anesthesia were randomly allocated into the control group (infusion with 0.9% normal saline after delivery and PCIA with sufentanil) and the DEX group (DEX infusion 0.5 μg/kg after delivery and PCIA with DEX plus sufentanil). The prevalence of postpartum depressive disorders was indicated by the Edinburgh Postnatal Depression Scale (EPDS). Postoperative analgesia, sedation, and sleep quality of parturients were also assessed. Results Postpartum blues and PDS prevalence in the DEX, versus control, group were significantly lower (5.0% vs 14.1%, p<0.001; 5.7% vs 16.3%, p<0.001, respectively), especially in parturients with antenatal depression or moderate stress during pregnancy. Compared with the control group, the EPDS score at postpartum days 7 and 42 in the DEX group was significantly lower (4.23 ± 4.37 vs 1.93 ± 3.36, p<0.001; 4.68 ± 4.78 vs 1.99 ± 3.18, p<0.001, respectively), as was the incidence of postpartum self‐harm ideation at postpartum days 7 and 42 in the DEX group versus the control group (1.1% vs 4.0%, p=0.03; 0.4% vs 2.9%, p=0.04, respectively). The pain score and the sleep quality in the DEX group were better than that in the control group (p<0.001). Conclusion The application of DEX in the early postpartum period can significantly attenuate the incidence of postpartum depressive disorders.

show abstract

“…A number of studies have recently suggested that smoking both during pregnancy and postnatally (Grover et al, 2012) are higher among women with mental health conditions compared to women without mental health problems (Goodwin et al, 2007). Recent studies also suggest that maternal depression during pregnancy is independently associated with risks to mental and physical health outcomes in offspring (Latendresse et al, 2015; Nkansah-Amankra and Tettey, 2015; Plant et al, 2016; Plant et al, 2015). Pregnant women with depression are also more likely to continue smoking in pregnancy than those without depression (Smedberg et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Smoking during pregnancy in the United States, 2005–2014: The role of depression

Goodwin

Cheslack‐Postava

Nelson

et al. 2017

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background Despite success of public health-oriented tobacco control programs in lowering the smoking prevalence over the past several decades, it is unclear whether similar reductions in smoking have been experienced among pregnant women, especially in vulnerable groups such as those with major depression and/or lower socioeconomic status. Objectives The purpose of this study is to examine the relationship between major depressive episode (MDE) and smoking among pregnant women overall, and by demographics and to estimate changes in the prevalence of cigarette smoking among pregnant women with and without MDE from 2005–2014. Study Design Cigarette use among pregnant women with and without MDE was examined using logistic regression models in the National Survey on Drug Use and Health. Results Prenatal smoking is more common among pregnant women with, compared to without, MDE (32.5% vs. 13.0%; (adjusted OR=2.50 (1.85, 3.40)), and greater disparities were revealed when also considering income, education and race. Over time, smoking during pregnancy increased significantly among women with MDE (35.9% to 38.4%; p=0.02)) and showed a decreasing trend among women without MDE (12.5% to 9.1%; p=0.07) from 2005–2014. Conclusions Over the past decade, smoking during pregnancy has increased among women experiencing a major depressive episode and is over four times more common among pregnant women with, than without, MDE. Disparities in smoking during pregnancy by MDE status and socioeconomic subgroups appear substantial. Given the multitude of risks associated with both MDE and smoking during the prenatal period, more work targeting this vulnerable and high-risk group is needed.

show abstract

Maternal depression during pregnancy and offspring depression in adulthood: Role of child maltreatment

Cited by 157 publications

References 56 publications

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

Dexmedetomidine Alleviates Postpartum Depressive Symptoms following Cesarean Section in Chinese Women: A Randomized Placebo‐Controlled Study

Smoking during pregnancy in the United States, 2005–2014: The role of depression

Contact Info

Product

Resources

About